SAR442501 / Sanofi - LARVOL DELTA

upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov) - P2 | N=16 | Terminated | Sponsor: Sanofi | Active, not recruiting ➔ Terminated; Sponsor decision. Not related to safety concern.

Trial termination • Genetic Disorders • Orthopedics • Pediatrics

upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov) - P2 | N=16 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | N=36 ➔ 16 | Trial completion date: Dec 2027 ➔ Feb 2025 | Trial primary completion date: Dec 2027 ➔ Feb 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Orthopedics • Pediatrics

upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Orthopedics • Pediatrics • BGLAP

upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Sanofi

New P2 trial • Genetic Disorders • Orthopedics • Pediatrics • BGLAP

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Sanofi

New P1 trial • Orthopedics